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Abstract
Aims/hypothesis Microvascular disease in type 2 diabetes is a significant cause of end-stage renal disease, blindness and
peripheral neuropathy. The strict control of known risk factors, e.g. lifestyle, hyperglycaemia, hypertension and dyslipidaemia,
reduces the incidence of microvascular complications, but a residual risk remains. Lipoprotein (a) [Lp(a)] is a strong risk factor
for macrovascular disease in the general population. We hypothesised that plasma Lp(a) levels and the LPA gene SNPs
rs10455872 and rs3798220 are associated with the incident development of microvascular complications in type 2 diabetes.
Methods Analyses were performed of data from the DiaGene study, a prospective study for complications of type 2 diabetes,
collected in the city of Eindhoven, the Netherlands (n = 1886 individuals with type 2 diabetes, mean follow-up time = 6.97 years).
To assess the relationship between plasma Lp(a) levels and the LPA SNPs with each newly developed microvascular complica-
tion (retinopathy n = 223, nephropathy n = 246, neuropathy n = 236), Cox proportional hazards models were applied and adjusted
for risk factors for microvascular complications (age, sex, mean arterial pressure, non-HDL-cholesterol, HDL-cholesterol, BMI,
duration of type 2 diabetes, HbA1c and smoking).
Results No significant associations of Lp(a) plasma levels and the LPA SNPs rs10455872 and rs3798220 with prevalent or
incident microvascular complications in type 2 diabetes were found. In line with previous observations the LPA SNPs
rs10455872 and rs3798220 did influence the plasma Lp(a) levels.
Conclusions/interpretation Our data show no association between Lp(a) plasma levels and the LPA SNPs with known effect on
Lp(a) plasma levels with the development of microvascular complications in type 2 diabetes. This indicates that Lp(a) does not
play a major role in the development of microvascular complications. However, larger studies are needed to exclude minimal
effects of Lp(a) on the development of microvascular complications.
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Abbreviations
ApoA Apolipoprotein A
EAS European Atherosclerosis Society
Lp(a) Lipoprotein A
MAP Mean arterial pressure
MDRD Modification of Diet in Renal Disease
Introduction
Microvascular complications greatly reduce the quality of life
of individuals with type 2 diabetes. Microvascular damage
causes end-stage renal disease, blindness and peripheral
neuropathy [1–3]. Strict control of risk factors (e.g. lifestyle,
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hyperglycaemia, hypertension and dyslipidaemia) reduces the
incidence of microvascular complications. However, even
when people with type 2 diabetes receive optimal treatment
according to the current standards, there is a residual risk of
development and progression of complications [4, 5]. Thus,
there is a need to identify additional risk factors. A better
understanding of these factors paves the way for better predic-
tion, prevention and treatment. Lipoprotein(a) [Lp(a)] is a
known strong risk factor for macrovascular disease in the
general population [6]. New therapies have emerged that
reduce Lp(a), and thereby could potentially decrease the
burden of macrovascular disease [7]. Microvascular disease
in type 2 diabetes could be a potential new target for Lp(a)-
lowering therapies. Lp(a) has been related to atherosclerosis
and macrovascular disease [6, 8]. Microvascular diseases
share underlying mechanisms with atherosclerosis and
macrovascular disease [9, 10]. We hypothesised that Lp(a) is
a risk factor for microvascular disease in type 2 diabetes.
Lp(a) is an LDL-like lipoprotein with an apolipoprotein
B-100 molecule, to which a unique apolipoprotein A (ApoA)
is attached via a disulfide bond. Lp(a) is considered to be amore
pro-thrombotic and atherogenic particle than LDL. Lp(a) plas-
ma levels are highly heritable and are associated with the size of
the ApoA protein, which is determined by the number of
kringle IV type 2 (KIV) repeats [11]. Furthermore, two well
investigated LPA SNPs, rs10455872 and rs3798220 influence
Lp(a) plasma levels, and are associated with a lower number of
Lp(a) KIV repeats [12]. In prospective, population-based stud-
ies, positive associations between Lp(a) plasma levels and
macrovascular disease have been reported [13, 14]. These find-
ings have been confirmed using the Mendelian randomisation
approach, which indicates a causal role of Lp(a). Lp(a) levels
≥30 mg/dl are associated with macrovascular disease. The
Copenhagen City Heart Study showed a 1.6-fold increased
risk for incident myocardial infarction for Lp(a) levels
between 30 and 76 mg/dl, corresponding to the 67th to 90th
percentile, this further risk increased with higher Lp(a) levels
[15]. Findings on the relationship of Lp(a) levels and micro-
vascular complications in type 2 diabetes have been conflict-
ing [16–27]. Most of these studies were of Asian populations
and the generalisability of the findings to other ethnicities
remains uncertain. Regarding diabetic retinopathy, two
cross-sectional studies and one prospective study found that
high Lp(a) levels significantly associate with diabetic retinop-
athy [16, 17, 23]. However, other cross-sectional studies did
not find any association [20, 22]. In diabetic nephropathy, two
small prospective studies found Lp(a) to be positively associ-
ated with nephropathy [19, 24], whereas another prospective
study by Lin et al [25] did not find any association. Similarly,
the few reports for diabetic neuropathy are also conflicting
[26, 27]. The association of known LPA SNPs and ApoA
isoforms with microvascular complications in type 2 diabetes
has never been investigated. We therefore investigated the
association of Lp(a) plasma levels and selected LPA SNPs
with prevalent and incident microvascular complications of
type 2 diabetes using data from the DiaGene study, a prospec-
tive case−control study on type 2 diabetes with follow-up on
microvascular complications [28].
Research in context
What is already known about this subject?
Lipoprotein(a) [Lp(a)] is a causal risk factor for the development of macrovascular complications in the general 
population, as confirmed by Mendelian randomisation studies
New therapies have emerged to potentially decrease Lp(a) levels
The risk factor profiles associated with the development of macro- and microvascular disease in type 2 diabetes
are similar to each other
What is the key question?
Is Lp(a) associated with the development of microvascular disease in type 2 diabetes?
What are the new findings?
Lp(a) plasma levels were not associated with prevalent or incident microvascular endpoints
Two LPA SNPs known to influence Lp(a) plasma levels were also not associated with microvascular endpoints
How might this impact on clinical practice in the foreseeable future?
Lp(a) plays no major role in the development of microvascular complications in type 2 diabetes, so potential new 
therapies lowering Lp(a) may not have a large effect in lowering the burden of microvascular disease in individuals 
with type 2 diabetes
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Methods
Study design The overall aim of the DiaGene study is to
unravel the aetiology of type 2 diabetes and its complica-
tions, by identifying risk factors, e.g. genomic, glycomic
and lipidomic factors. The design of the DiaGene study has
been reported elsewhere [28]. Briefly, the DiaGene study is
an all lines of healthcare prospective case−control study
collected of individuals resident in and around the city of
Eindhoven in the Netherlands. All hospitals in this area
participated, as well as the centre for primary care diagnos-
tics. Hence, virtually all individuals with type 2 diabetes in
this area were approached for inclusion. Initially, 2065
patients were included by physicians at all centres. Of
these, 179 patients were excluded. Reasons for exclusion
were: no diabetes, type 1 diabetes, maturity-onset diabetes
of the young, latent auto-immune diabetes in adults, double
inclusion of the participant, post-pancreatitis diabetes,
withdrawal of consent during the study period and missing
informed consent. Finally, 1886 patients with type 2 diabe-
tes and 854 controls were included in the DiaGene study,
which consisted mostly of people of European descent.
Written informed consent was obtained from all partici-
pants. This study was approved by the medical ethics
committees of the Erasmus MC and the local hospitals in
Eindhoven. For the analyses described in this paper, only
data on type 2 diabetes cases were analysed.
Clinical data Laboratory data and anthropometrics were
derived from medical records at inclusion. By means of a
questionnaire, medical history, family history and lifestyle
information were collected. Mean arterial pressure (MAP)
was calculated with the formula (2 × diastolic pressure +
systolic pressure)/3. Non-HDL-cholesterol was calculated
with the formula non-HDL-cholesterol = total cholesterol –
HDL-cholesterol.
Definitions of microvascular complications Diabetic retinopa-
thy was scored by ophthalmologists as absent or present,
according to the Dutch guideline for diabetic retinopathy
[29]. If present, it was classified as non-proliferative, prolifer-
ative, treated with photo-coagulation or treated with intra-
vitreal injections. Neuropathy was diagnosed by a podiatrist,
neurologist or the treating physician and graded according to
the Sims classification [30]. Neuropathy data were only avail-
able for those individuals with type 2 diabetes who were under
surveillance in outpatient clinics (n = 796). Nephropathy was
defined as microalbuminuria (ACR ≥2.5 mg/mmol for men or
≥3.5 mg/mmol for women) at two of three consecutive
measurements, or when high microalbuminuria or
macroalbuminuria was present at one measurement (ACR
≥12.5 mg/mmol for men and ≥17.5 mg/mmol for women)
[28].
Lp(a) plasma concentration and Lp(a) SNPs Venous blood
samples were drawn from individuals with type 2 diabetes
at enrolment; after centrifugation, the plasma and buffy
coat were separated. Plasma samples were directly stored
at –80°C. Lp(a) concentrations were measured in samples
that had not been defrosted previously. Lp(a) concentra-
tions in plasma were measured with the KIV-2 number-
independent Randox immunoassay on a Roche Cobas
c501 Chemistry Analyzer [31, 32], with an Lp(a) concen-
tration range of 3–300 mg/dl. A total of 1850 type 2 diabet-
ic individuals with successfully measured Lp(a) plasma
levels were included in the analyses. LPA SNPs
rs10455872 and rs3798220 were genotyped by using
Taqman allelic discrimination assays designed and
optimised by Applied Biosystems (Foster City, CA,
USA). The LPA SNPs rs10455872 and rs3798220 were
successfully genotyped for 1696 (90%) and 1727 (92%)
participants, respectively. Reactions were performed on
the Taqman Prism 7900 HT platform.
Statistical analysis To compare baseline variables, the inde-
pendent samples t test was used for continuous variables with
a normal distribution and theMann–Whitney test was used for
continuous variables with a non-normal distribution.
Normality was assumed when skewness and kurtosis were
within the range of −1 and +1. For categorical variables, the
χ2 test was applied. To assess the relationship between Lp(a)
and microvascular endpoints, we used Lp(a) plasma levels as
an independent primarily binary variable (<30 mg/dl and
≥30 mg/dl). This cut-off level is based on clinical studies in
the general population, where an almost two times higher risk
of a major adverse cardiovascular event is present when Lp(a)
plasma levels exceed 30 mg/dl [15]. However, specifically for
stroke, the ‘Emerging risk factors consortium’ observed a
higher threshold of Lp(a) concentrations [14]. In addition,
we assessed the relationships of the microvascular complica-
tions with Lp(a) as a continuous variable and in categorical
quartiles. For prevalent microvascular complications at base-
line, logistic regression was used to assess the relationship of
Lp(a) and each of the microvascular complication endpoints.
Cox proportional hazards models were used to prospectively
assess the association between Lp(a) as an independent vari-
able and each microvascular complication endpoint as a
dependent variable. The prevalent cases at baseline were
excluded from the prospective analyses. In addition, to assess
the association of Lp(a) with kidney function, estimated
glomerular filtration rate (eGFR) determined by the
Modification of Diet in Renal Disease (MDRD) study equa-
tion [33], we performed linear regression, with% difference in
eGFR as the dependent variable and Lp(a) the independent vari-
able. The% difference in eGFRwas calculated using the formu-
la ([eGFRbaseline – eGFRfollow-up]/eGFRbaseline) × 100. Model 1
was adjusted for sex and age. Model 2 was adjusted for the
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following additional risk factors for microvascular complica-
tions: MAP, non-HDL-cholesterol, HDL-cholesterol, HbA1c,
BMI, duration of type 2 diabetes and smoking. In order to detect
whether there was any other form of relationship we may have
missed by analysing Lp(a) linearly or in quartiles, we performed
non-linear spline analyses. More specifically, we applied P-
splines (penalised cubic B-splines) in both the logistic regression
as well as Cox models [34]. This involves selecting a high
number of equidistant knots, followed by a penalty term, which
is optimised via generalised cross validation to avoid overfitting.
This is a data-driven and explorative approach for detecting any
non-linear relationships. Models 1 and 2 described above were
also applied to assess the relationship between the SNPs and
each microvascular endpoint. For analysing this relationship
between the SNPs rs10455872, rs3798220 and microvascular
endpoints an additive genetic model was used. To assess if LPA
SNPs carrier status associates with Lp(a) plasma concentration,
one-way ANOVAwas applied. We tested the Hardy–Weinberg
equilibrium before incorporating the LPA SNPs in the analyses.
A p value of <0.05 was considered statistically significant.
Statistical analyses were performed using SPSS 25.0 (IBM,
Armonk, NY, USA). Non-linear spline analyses were performed
using R version 3.6.0 (https://www.r-project.org/), including
packages ‘mgcv’ and ‘survival’. For cross-sectional and
prospective analyses concerning Lp(a) as binary predictor, we
had 80% power to detect anOR of 1.4 and anHR of 1.5 for each
microvascular endpoint, respectively. And for cross-sectional
and prospective analyses with Lp(a) as continuous predictor,
we had 80% power to detect an OR of 1.09 and an HR of
1.013 for each microvascular endpoint, respectively.
Moreover, for genetic analyses, we had 80% power to detect
an HR of 1.7 for each separate SNP (rs10455872 and
rs3798220) separately. ESM Table 1 provides an overview of
conducted post hoc power analyses [35–37].
Results
Baseline characteristics of the study population The baseline
characteristics and the number (and percentage) of individuals
with data missing per characteristic of the study population are
shown in Table 1. The age of the participants ranged from 27
to 94 years, with a mean age of 65.2 years; 46% were female.
The mean duration of type 2 diabetes before the baseline
investigation was 10.02 years, mean duration of follow-up
from baseline was 6.97 years. In the total population, mean
Lp(a) was 27.40 mg/dl and the median was 11.00 mg/dl. ESM
Table 2 shows the Lp(a) median concentration according to
each of the microvascular complications. The prevalence of
retinopathy, nephropathy and neuropathy was 17%, 23% and
31%, respectively (Table 1). The incidence of retinopathy,
nephropathy and neuropathy was 16%, 19% and 49.2%,
respectively. Of note, data regarding the prevalence and
incidence of neuropathy were available only for the 796 indi-
viduals who attended the outpatient clinic. Among the indi-
viduals free of a microvascular complication at baseline, those
who developed microvascular complications during follow-
up were significantly older (65.0 ± 10.4 vs 58.6 ± 11.6 years,
p < 0.001), had a later age of onset of type 2 diabetes (54.70 ±
12.61 vs 47.61 ± 11.43 years, p < 0.001), a longer duration of
type 2 diabetes (12.44 ± 8.89 vs 11.05 ± 6.28, p = 0.043) and
higher MAP (98.41 ± 10.14 vs 95.54 ± 7.85 mmHg, p =
0.005) than those who were did not develop microvascular
complications.
Lp(a) and prevalent complications at baseline In cross-
sectional analyses at baseline (ESM Table 3), individuals with
type 2 diabetes with Lp(a) concentrations ≥30 mg/dl did not
have significantly higher ORs than those with concentrations
<30 mg/dl for each of the microvascular endpoints in any of
the models. These results did not change when the separate
endpoints were taken together as one composite endpoint (OR
0.95, 95% CI 0.70, 1.27, p = 0.71). Additional analyses with
Lp(a) as a continuous variable or divided into quartiles did not
change these results (ESM Tables 4, 5). Furthermore, spline
analyses for Model 2 did not argue for any other non-linear
relationship with prevalent microvascular endpoints (ESM
Fig. 1, all p values for deviation from linearity >0.99).
Lp(a) and incident complications at follow-up Table 2 shows
the Cox proportional hazards models of the prospective anal-
yses. Individuals with Lp(a) concentrations ≥30 mg/dl did not
have significant HRs for any of the microvascular endpoints in
any of the models. Similarly, Kaplan–Meier curves created for
each microvascular endpoint did not show any significant
difference between the two Lp(a) concentration groups (Fig.
1). Consideration of the three microvascular endpoints togeth-
er as one composite endpoint in the Cox proportional hazards
regression did not change the result (HR 1.16, 95% CI 0.85,
1.60, p = 0.35). Additional analyses with Lp(a) as a continu-
ous variable or divided into quartiles did not change these
results (ESM Tables 4 and 5). Investigation of the relationship
with kidney function defined by eGFR MDRD revealed that
Lp(a) was not significantly associated with percentage eGFR
MDRD decline during follow-up (ESM Table 6).
Furthermore, spline analyses for Model 2 also did not show
any non-linear relationship of Lp(a) concentration with inci-
dent microvascular endpoints (ESM Fig. 2, all p values for
deviation from linearity >0.28).
LPA genotypes and Lp(a) concentrations For the entire study
population independent of microvascular complications at
baseline the LPA SNPs rs10455872 and rs3798220 were in
Hardy–Weinberg equilibrium (χ2 2.20, p > 0.05 and χ2 0.86,
p > 0.05), respectively. Minor allele frequencies of
rs10455872 and rs3798220 were 0.0648 and 0.0156,
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respectively (see details on genotype distribution and mean
Lp(a) plasma concentration according to the carrier status of
the LPA SNPs in Table 3). Individuals with at least one minor
allele for rs10455872 and rs3798220 had significantly higher
Lp(a) plasma concentrations compared with individuals with
the wild-type genotype. The SNPs rs10455872 and rs3798220
explained 20% and 8% of the variation in Lp(a) levels, respec-
tively, and jointly explained 30% of the variance.
LPA SNPs and incident microvascular complications ESM
Table 7 shows the Cox proportional hazards models for
prospective analyses of the LPA SNPs, according to the addi-
tive genetic model. For both LPA SNPs, carriers of the minor
allele did not have significant HRs for any of themicrovascular
complications. These results did not change when the separate
microvascular endpoints were taken together as one composite
endpoint (data not shown). Furthermore, these results did not
change when analysing the two SNPs together as a genetic risk
score (ESM Table 8).
Discussion
In our cohort study of type 2 diabetes individuals, we did not
find a cross-sectional nor a prospective association of Lp(a)
Table 1 Baseline characteristics
of the study population with
successfully measured Lp(a)
levels
Characteristic Cases (n = 1850) n (%) missing data
Female sex, n (%) 857 (46%) 1 (0.1%)
Age (years) 65.20 (10.54) 1 (0.1%)
Age of onset diabetes (years) 54.94 (11.71) 118 (6%)
Duration of diabetes (years) 10.02 (8.40) 118 (6%)
Duration of follow-up (years) 6.97 (2.10) 11 (0.6%)
BMI, (kg/m2) 29.50 (27.00–33.05) 129 (7%)
HbA1c (mmol/mol) 50.82 (45.46–59.57) 92 (5%)
HbA1c (%) 6.80 (6.30–7.60) 92 (5%)
MAP (mmHg) 98.97 (10.80) 126 (7%)
Total cholesterol (mmol/l) 4.29 (0.93) 90 (5%)
Triacylglycerols (mmol/l) 1.43 (1.02–2.04) 92 (5%)
HDL-cholesterol (mmol/l) 1.10 (0.93–1.32) 93 (5%)
Non-HDL-cholesterol (mmol/l) 3.12 (0.90) 93 (5%)
LDL-cholesterol (mmol/l) 2.45 (0.83) 120 (6%)
Lp(a) (mg/dl) 27.40 (42.09) 0
Lp(a) (mg/dl) 11.00 (5.00–31.55) 0
Lp(a) ≥30 mg/dl, n (%) 483 (26%) 0
Creatinine (μmol/l) 77.00 (67.00–92.00) 121 (7%)
eGFR (MDRD) (ml min–1 [1.73 m]−2) 77.36 (22.48) 121 (7%)
Outpatient clinic patients, n (%) 796 (43%) -
Smoking, n (%) 177 (10%)
Never 433 (26%)
Former 943 (56%)
Current 297 (18%)
Microvascular complications at baseline
Retinopathy at baseline, n (%) 298 (17%) 105 (6%)
Nephropathy at baseline, n (%) 375 (23%) 199 (11%)
Neuropathy at baseline, n (%)a 223 (31%) 1118 (60%)
Microvascular complications during follow-up
Retinopathy during follow-up, n (%) 223 (16%) 156 (8%)
Nephropathy during follow-up, n (%) 246 (19%) 107 (6%)
Neuropathy during follow-up, n (%)a 236 (32%) 1123 (61%)
Unless stated otherwise, mean (±SD) are given for normally distributed covariates. For non-normally distributed
covariates, median and IQR are given
a Information only available for individuals who attended an outpatient clinic (n = 796)
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plasma levels and LPA SNPs rs10455872 and rs3798220 with
microvascular complications.
In the general population, Lp(a) is a causal risk factor for
macrovascular complications [38]. The risk factor profiles
associated with the development of macro- and microvascular
disease in type 2 diabetes are thought to be similar [39]. If so,
microvascular disease could be an extra target for the newly
developed ApoA antisense therapy [40]. In our large prospec-
tive study, elevated Lp(a) concentrations were not associated
either with prevalent or incident microvascular endpoints in
type 2 diabetes. Our results are strengthened by the lack of
association of the LPA SNPs rs10455872 and rs3798220,
which, notably, did have their known significant effects on
Lp(a) plasma levels. Moreover, in our DiaGene cohort the
two SNPs rs10455872 and rs3798220 explained 20% and
8% of the variation in Lp(a) levels, respectively, and jointly
explained 30% of the variance. This is relatively high
compared with other type 2 diabetes populations (of about
1000 individuals), where rs10455872 explained approximate-
ly 3% of the Lp(a) variation [41]. However, in the general
population, Clarke et al found that these two SNPs together
explained 40% of the Lp(a) variation [12]. Overall, in our
DiaGene cohort the variance explained by the SNPs is in line
with the findings in the general population. Overall, our
results indicate that Lp(a)-lowering therapies might not have
a place in the treatment of microvascular complications in type
2 diabetes. Differences with previously reported results are
unlikely to be explained by heterogeneity based on the differ-
ences between cross-sectional and prospective study designs,
as we performed both and found virtually identical results.
Factors that potentially contributed to the variation between
the findings of the studies are ethnicity, conditions for and
duration of storage of plasma samples, and method of Lp(a)
measurement, which we will discuss below.
The two prospective analyses in a South Korean population
by Yun et al pointed at a positive association between Lp(a)
plasma levels and both diabetic retinopathy and nephropathy
[19, 23]. One prospective study, on kidney function decline, not
strictly confined to nephropathy, in individuals of European
descent with type 2 diabetes found no association with Lp(a)
levels, in line with our findings [25]. Ethnicity is associated
with differences in Lp(a) plasma levels; higher levels are found
in black compared with white populations, and a significant
heterogeneity has been reported across Asian populations, with
lower levels observed in Chinese than in Indian populations
[42, 43]. These ethnic differences may be explained by genetic
and environmental differences [44]. Notably, the ethnic differ-
ences in plasma levels of Lp(a) were not detectable at birth [45].
Macrovascular disease risk that associated with elevated Lp(a)
levels also showed differential effects across different ethnici-
ties [46]. However, it remains unknown whether and how
ethnicity contributes to differential effects of Lp(a) on micro-
vascular disease, ranging from no effect in individuals from
European descent to increased risk in South Koreans.
Sample storage and method used to determine Lp(a) plasma
concentration both influence measurements [32, 47]. Several
studies have measured Lp(a) directly after venous blood with-
drawal, whereas others first stored the samples in freezers, at
different freezing temperatures. Kronenberg et al [47] showed
that Lp(a) plasma levels decline over time when stored frozen,
with a further decline observed with multiple thawing cycles.
Samples stored at −20°C declined at significantly faster rate
than those stored at −80°C [47]. Most of the studies so far,
including the reports by Yun et al [19, 23], did not perform a
KIV size-independent method, resulting in analyses with
‘biased’ Lp(a) levels [16–18, 20, 22, 24–27]. Marcovina et al
[48] showed that these biases among methods of Lp(a) plasma
measurement can substantially affect the outcomes. We have
measured Lp(a) in previously unthawed samples (stored at
−80°C) with a KIV size-independent method.
In our type 2 diabetes population, Lp(a) levels were rela-
tively low compared with reports in the general population
[13]. Individuals with type 2 diabetes are often in a
hyperinsulinaemic state as a result of peripheral insulin resis-
tance. Hyperinsulinaemia decreases Lp(a) plasma levels, as
insulin suppresses ApoA production in hepatocytes at the
post-transcriptional level [49]. One may speculate that, in type
2 diabetes, high Lp(a) levels do not contribute to
Table 2 Hazard ratios for inci-
dent microvascular complications
for patients with Lp(a) concentra-
tions ≥30 mg/dl <30 mg/dl
(reference group)
Model 1, HR (95% CI) p value Model 2, HR (95% CI) p value
Retinopathy (n = 183)
≥30 mg/dl 0.94 (0.69, 1.26) 0.66 1.02 (0.73, 1.43) 0.90
Nephropathy (n = 185)
≥30 mg/dl 1.04 (0.78, 1.38) 0.81 1.03 (0.73, 1.44) 0.88
Neuropathy (n = 202)
≥30 mg/dl 0.99 (0.74, 1.33) 0.95 0.99 (0.70, 1.39) 0.94
n, numbers of patients who developed the complication
Model 1: adjusted for sex and age
Model 2: additionally adjusted for MAP, non-HDL-cholesterol, HDL-cholesterol, BMI, duration of type 2 diabe-
tes, HbA1c and smoking (never/former/current)
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microvascular disease risk, because of other more influential
competing risk factors, such as hyperglycaemia and
dyslipidaemia. However, even the highest quartiles of Lp(a)
levels did not display any association with microvascular
complications, suggesting that there may be no role for
Lp(a) in these endpoints at all.
Finally, the KIV size remains an essential property of
Lp(a). The KIV size is independently inversely associated
with macrovascular disease in the general population [50].
Likewise, it could be independently associated with microvas-
cular complications in type 2 diabetes. Unfortunately, we do
not have details of the KIV size. As it is known that Lp(a)
plasma levels are inversely associated with the KIV size, if
this effect on microvascular disease is substantial, we would
have expected to find a positive association of Lp(a) plasma
levels with microvascular complications. Also, the investigat-
ed LPA SNP rs10455872 is strongly associated with the KIV
size and showed no association with our microvascular
endpoints [51]. However, we cannot exclude the possibility
that the KIV size is associated with microvascular disease, and
this will be the subject of ongoing studies in our population.
Strengths of our study are the prospective study design, rela-
tively large type 2 diabetes cohort, the meticulous collection of
phenotypic and risk factor data, the investigation of all micro-
vascular endpoints and the concomitant investigation of the
effects of LPA SNPs. Moreover, we used an immunoassay with
the least Lp(a) concentration-dependent bias of the available
immunoassays, and this immunoassay has a correlation coeffi-
cient (r) of 0.99 with values determined by the ‘gold standard’
for measuring Lp(a) (an ELISA method) [32, 47]. Furthermore,
we directly stored our plasma samples in minus 80°C and used
previously unthawed samples [47]. Although we performed our
study with great care, we need to consider some limitations. We
had 80% power to detect an HR of 1.5 for the categorical and
1.013 for the continuous analyses. All analyses in Model 2
resulted in ORs and HRs for microvascular disease very close
to 1.0, with 95% confidence upper limits of around 1.5 for the
categorical analyses and 1.005 for a continuous increase of
1 mg/dl. This means that true effect sizes larger than these upper
limits are highly unlikely, but effect sizes within the 95% confi-
dence intervals cannot be excluded to become significant in
much larger studies. To put this into context, a 0.8% difference
Lp(a)
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Fig. 1 Kaplan–Meier curves for the percentage of the study population who developed retinopathy (a), nephropathy (b) or neuropathy (c) during follow-
up according to Lp(a) level
Table 3 Distribution and associ-
ation LPA SNPs with Lp(a)
concentrations
SNP n (%) Mean Lp(a) Median Lp(a) p value
rs10455872
Wild-type (AA) 1514 (87.6%) 20.95 (35.01) 9.00 (4.00–20.30) 2.35 × 10−86
Heterozygous (AG) 202 (11.7%) 70.58 (52.21) 62.00 (47.00–78.50)
Homozygous (GG) 11 (0.7%) 158.76 (62.12) 167.00 (96.90–203.00)
rs3798220
Wild-type (TT) 1644 (96.9%) 25.23 (37.12) 11.00 (5.00–30.00) 4.33 × 10−31
Heterozygous (TC) 51 (3%) 94.04 (97.88) 74.95 (7.25–155.50)
Homozygousa (CC) 1 (0.1%) 74.00 (NA) NA
Mean (± SD), median (IQR) are given
a n = 1, SD not applicable (NA)
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in HbA1c, as a known continuous risk factor for microvascular
disease, in the Action in Diabetes and Vascular Disease:
Preterax and Diamicron MR Controlled Evaluation
(ADVANCE) study resulted in an HR of 1.14 (95% CI 1.03,
1.23) for microvascular disease after 5 years of follow-up [52].
This confidence interval does not contain the higher upper
limit of the 95% CI in our study of HR 1.005. In even larger
studies, our HR of 1.005 per 1 mg/dl increasing Lp(a) level
could potentially become statistically significant and have an
effect on microvascular disease risk, although this would be a
very small effect. Furthermore, neuropathy data were only
available for individuals who were seen as outpatients in the
hospitals, so we cannot generalise our findings to the first line
of care. In addition, data on KIV size are not available for our
study population.
In conclusion, our data indicate that Lp(a) plasma levels do
not play a major role in the development of microvascular
complications in individuals from European descent with type
2 diabetes. Larger studies than ours may be able to detect very
small effects of Lp(a) levels on these outcomes. Future studies
taking the Lp(a) KIV size into account can further elucidate
whether or not any other aspect of the Lp(a) particle is associ-
ated with the microvascular complications of type 2 diabetes.
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